The Effect of Rongdan Oral Liquid on Patients with Diabetic Peripheral Neuropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TTRCC-13004808

Enrollment

Unknown

Registered

2013-07-21

Start date

2014-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Interventions

one:Rong-dan oral liquid (20ml tid)

two:Mecobalamin Tablets(500ug tid)

Eligibility

Sex/Gender

All

Age

15 Years to 100 Years

Inclusion criteria

Inclusion criteria: type 2 diabetic patients with DPN which were abnormal results of EMG examination, glycated hemoglobin = 8% and signed informed consents

Exclusion criteria

Exclusion criteria: (1) Type 1 diabetes and secondary diabetes; (2) the presence of diabetes emergency such as: acute infection, stress, perioperative use of corticosteroids, acute heart, brain, kidney failure status; (3) the existence of a history of diabetic ketoacidosis or hyperosmolar nonketotic coma; (4) allergy with Dan Rong oral; (5) HbA1c> 8%

Design outcomes

Primary

Measure	Time frame
nerve conduction velocity;symptom;HbA1c;	—

Countries

China

Contacts

Public ContactChen Xiaoyan

The first affiliated hospital of Guangzhou medical university

gzscxy@126.com+86 18928868167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026